Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CDK14 | O94921 | 8/20 | 0.52 |
| ▸ | CCNY | Q8ND76 | 8/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12288164 | 0.88 | CDK14 (0.53) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL8260751 | 0.86 | CDK14 (0.51) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL954955 | 0.86 | KMT2A (0.51) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL5784308 | 0.85 | KMT2A (0.57) | KMT2AMEN1POLBJAK2TYK2 | |
| SCHEMBL8261624 | 0.85 | CDK14 (0.50) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL3587209 | 0.84 | POLB (0.48) | KMT2AMEN1POLBABL1SRC | |
| SCHEMBL25649653 | 0.82 | KMT2A (0.49) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL8262556 | 0.82 | CDK14 (0.48) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL4488401 | 0.82 | CDK14 (0.48) | KMT2AMEN1POLBCDK14CCNY | |
| SCHEMBL5007605 | 0.81 | CDK14 (0.46) | KMT2AMEN1POLBCDK14CCNY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081789-A | Pyrazole derivative with antitumor activity and preparation method and application thereof | 天津匠新致成科技有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12187701-B2 | Taire family kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3810132-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112367991-A | TAIRE family kinase inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-1846393-B1 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-1846393-B1 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | KMT2A 3563/4885MEN1 1260/4885POLB 935/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | KMT2A 3563/4885MEN1 1260/4885POLB 935/4885 |
| US-12187701-B2 | Taire family kinase inhibitors and uses thereof | CDK14, CDK16, CDK19 | KMT2A 3563/4885MEN1 1260/4885POLB 935/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | KMT2A 1433/4885MEN1 3054/4885POLB 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.